| |
Step 1
|
Step 2
|
|---|
|
(n = 22)
|
(n = 15)
|
|---|
|
Sex, Male
|
15 (68)
|
13 (87)
|
|
Age, year (mean [range])
|
68 (56–78)
|
66 (49–76)
|
|
Weight, kg (mean [range])
|
55 (40–85)
|
55 (42–70)
|
|
Height, cm (mean [range])
|
162 (148–178)
|
165 (160–173)
|
|
Cancer typea
|
|
Gastric
|
16 (73)
|
9 (60)
|
|
Esophageal
|
4 (18)
|
6 (40)
|
|
Colorectal
|
1 (5)
|
0 (0)
|
|
NSCLC
|
2 (9)
|
0 (0)
|
|
Thyroid
|
1 (5)
|
0 (0)
|
|
Primary tumor
|
|
Present
|
11 (50)
|
8 (53)
|
|
Prior cancer therapy
|
|
Chemotherapy
|
22 (100)
|
15 (100)
|
|
No. of regimens (mean [range])
|
4.4 (2–7)
|
4.5 (2–8)
|
|
Surgery
|
10 (46)
|
8 (53)
|
|
Radiation
|
3 (14)
|
4 (27)
|
|
EPHA2 expressionb
|
|
0
|
10 (46)
|
0 (0)
|
|
1+
|
2 (9)
|
0 (0)
|
|
2+
|
6 (27)
|
13 (87)
|
|
3+
|
1 (5)
|
2 (13)
|
- N (%) unless otherwise stated
- Abbreviations: NSCLC, non–small-cell lung cancer; EPHA2, erythropoietin-producing hepatocellular receptor A2
- aPatients with more than one type of cancer were repeatedly counted
- bData were presented only for patients who have been examined for EPHA2 expression
